Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
RO7247669 is a bispecific antibody that targets both PD-1 (PDCD1; CD279) and the lymphocyte activation gene 3 protein (LAG3), potentially resulting in decreased inhibition of T-cell activation and proliferation, and increased anti-tumor cytotoxic T-lymphocyte response (NCI Drug Dictionary).
|DrugClasses||LAG3 Antibody 17 PD-L1/PD-1 antibody 95|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Bevacizumab + RO7247669||Bevacizumab RO7247669||0||0|
|RO7247669 + Tiragolumab||RO7247669 Tiragolumab||0||1|